Form 4: Inovio Pharmaceuticals Director Ann Calby Miller Reports Stock and Option Awards

Director Ann Calby Miller reports acquisition of stock options and restricted stock units in Inovio Pharmaceuticals.

Summary

• Ann Calby Miller, a director of Inovio Pharmaceuticals, reported the acquisition of 2,917 common stock options and 2,167 restricted stock units on May 21, 2024.
• The options have an exercise price of $10.99 and vest 100% on May 21, 2025, expiring on May 21, 2034.
• The restricted stock units also vest 100% on May 21, 2025, and each unit represents a contingent right to receive one share of common stock.
• Following these transactions, Miller directly owns 2,917 shares of Inovio Pharmaceuticals common stock.

Sentiment

Score: 6

Explanation: The document is a routine SEC filing related to director compensation. It doesn't contain any particularly positive or negative news, but the granting of equity can be seen as a positive sign of aligning interests.

Positives

• The grant of stock options and restricted stock units to a director aligns their interests with those of the shareholders.
• The vesting schedule encourages continued service and contribution to the company.

Industry Context

Stock option and RSU grants are common practice in the pharmaceutical industry to incentivize and retain key personnel, aligning their interests with the long-term success of the company.

Comparison to Industry Standards

• Stock option grants to directors are a standard practice across the pharmaceutical industry.
• Companies like Moderna and BioNTech also utilize stock options and RSUs as part of their director compensation packages.
• The vesting schedules, typically one year, are also in line with industry norms.

Stakeholder Impact

• The grant of stock options and restricted stock units to a director can have a positive impact on shareholders by aligning the director's interests with the company's long-term success.

Key Dates